



5. <http://www.medscape.com/viewarticle/407713>
6. IMS, PharmMIS, Pharmexpert, 2010.
7. Barbić-Zagar B, Vozelj S, Ramipril - an effective drug for the treatment of arterial hypertension, *Kardio list*. 2008;3(4-5):39-40.
8. Vertkin AL, Skotnikov AS. Investigation of converting enzyme inhibitors in patients, survivors of myocardial infarction. *Kardiologija*. 2008;48(7):14-7.
9. Vertkin AL, Skotnikov AS. The role of ACEi in the treatment of acute myocardial infarction and during post infarction period. *RMJ Kardiologija*. 2009;17(19):1-6.
10. Malchikova SV, Tarlovskaya YI, Sheshukova SD. Pleiotropic potential of Amprilan in systemic hypertension in combination to ischemic heart disease. *Rossiyskie medicinskie vesti*. 2010;15(1):2732.
11. Vikulova OK, Yarek-Martynova IR, Trubitsina NP, Shestakova MV. Improvement of parameters of elasticity of arterial wall with correction of arterial pressure in patients with type 2 diabetes mellitus. *Kardiologija*. 2008;48(11):47-52.
12. Ishmanova AP, Zakhirova AN, Karamova IM, et al. The influence of the therapy with Amprilan (ramipril) and Tenox (amlodipin) on vasodilatory endothelial function, metabolic profile and arterial hypertension and metabolic syndrome in post menopausal period. *Kardiovaskuljarnaja terapija i profilaktika*. 2010;9(1):58-63.
13. Ktacheva ON, Barabashkina AV, Novikova IM, Runikhina NK. The study of effects of combination of Amprilan and Tenox in patients with arterial hypertension and type 2 diabetes mellitus. *Kardiologija*. 2009;5:40-7.
14. Majanska SD, Kukumadžan NV, Majer SV. Comparative evaluation of nephroprotective effect of ramipril in men and women with arterial hypertension and ischemic heart disease. *Problems in Women's Health*. 2008;2(3):68-73.
15. Drapkina OM, Ashikhmin YI, Ivashkin VT. Complexities of clinical diagnostics and treatment of diastolic chronic heart failure at patients with systemic hypertension. *Rossiyskie Medicinskie Vesti*. 2009;9(2):14-28.
16. Sokolova LA, Jeremenko JJ, Jegorova JA. The possibilities of using ACE inhibitors - ramipril in the prophylaxis of atrial fibrillation in patients with arterial hypertension, complicated with left ventricular hypertrophy. *Kardiologija*. 2009;6(50):338-42.

Ispravak

Errata corrige! U članku "Knežević A. Prednosti perindopрила u svim međusobno povezanim kardiovaskularnim zbivanjima: razina dokaza. (*Kardio list*. 2011;6(7-8):112-116.)" u tiskanoj inačici lista pogreškom nisu otisnuti literaturni navodi.

Uredništvo lista ispričava se autoru i čitateljima, a popis literaturnih navoda slijedi u nastavku.

Literature

1. Opie LH, Pfeffer MA. Inhibitors of angiotensin-converting enzyme, Angiotensin II receptor, aldosterone and renin. In: Opie LH, Gersh BJ. *Drugs for the heart*, Saunders 2009.
2. The Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*. 2000;342:145-53.
3. The European trial on reduction of cardiac events with perindopril in patients with stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*. 2003;362:782-8.
4. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. *N Engl J Med*. 2004;351:2058-68.
5. Van Gilst WH. IMAGINE- Ischemia management with accupril post bypass graft via inhibition of angiotensin converting enzyme. Program and abstracts of the ESC Congress 2005; September 3-7,2005; Stockholm, Sweden. Hotline II.
6. Ong HT. Are ACE and ARB especially useful for cardiovascular protection. *J Am Board Fam Med*. 2009;22:686-97.
7. Brugts JJ, Ferrari R, Simoons ML. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. *Exp Rev of Cardiovasc Ther*. 2009;7:345-66.
8. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*. 2005;366:895-906.
9. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007;370:829-40.
10. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet*. 2001;358:1033-41.
11. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*. 2008;358:1887-98.

Erratum

Correction notice to the article: In the article, "Knežević A. Benefits of perindopril all along the cardiovascular continuum: the level of evidence. (*Kardio list*. 2011;6(7-8):112-116.)" literature references were erroneously not indicated in the printed version.

The Editorial board apologizes to the author and readers, while the list of literature references is indicated below.